White Goosefoot Allergy: A Major Late-Summer Weed Pollen Trigger

White goosefoot (Chenopodium album), also called lamb's quarters, is one of the most widespread and abundant weed species on Earth. It is an annual plant in the Amaranthaceae family that thrives in disturbed soils — agricultural fields, roadsides, construction sites, and gardens — across all 50 US states. It is particularly abundant in the Midwest, Great Plains, and California's Central Valley, where it is a dominant agricultural weed in corn, soybean, and wheat fields. The plant can grow up to six feet tall and produces enormous quantities of lightweight, wind-dispersed pollen from midsummer through early autumn. Its common name comes from the shape of its leaves, which resemble a goose's foot, and its mealy white coating on young leaves.

White goosefoot and ragweed are both major late-summer weed pollen allergens, but they differ in several important ways. Ragweed (Ambrosia) is the dominant weed allergen in the eastern US and is a member of the Asteraceae family, while white goosefoot (Chenopodium album) is in the Amaranthaceae family and is more dominant in the Midwest and Great Plains. Their pollen seasons overlap significantly — both peak in August and September — making it difficult to distinguish them by symptoms alone. The key molecular difference is that ragweed's major allergen, Amb a 1, is a pectate lyase, while goosefoot's major allergen, Che a 1, is a profilin. This means goosefoot sensitization drives broader cross-reactivity with other pollens and plant foods than ragweed sensitization typically does. Specific IgE testing or skin prick testing with both extracts is required to determine which weed is the primary driver of a patient's symptoms.

Anaphylaxis from inhaled white goosefoot pollen is exceedingly rare and has not been documented as a distinct clinical entity in the published literature. Like other pollen allergies, the primary presentation is rhinoconjunctivitis — sneezing, nasal congestion, itchy eyes — and occasionally mild asthma. Pollen inhalation does not deliver the large bolus of allergen protein typically required to trigger systemic anaphylaxis. However, patients with profilin sensitization via Che a 1 who consume large amounts of raw profilin-containing foods (such as melons or tomatoes) during the pollen season could theoretically experience more than mild oral symptoms, though this is uncommon. Any patient who experiences throat swelling, difficulty breathing, widespread hives, or dizziness after exposure to pollen or plant foods should seek emergency medical care immediately.

Yes, white goosefoot (lamb's quarters) extract is available as part of standard regional weed pollen skin prick test panels used by allergists in the United States. It is typically included alongside ragweed, sagebrush, Russian thistle, and amaranth in weed pollen panels for patients with late-summer allergic rhinitis. However, a positive goosefoot skin test does not necessarily mean goosefoot is the primary driver of symptoms — because Che a 1 is a profilin, a positive result may reflect cross-reactive sensitization from another pollen profilin rather than genuine goosefoot-specific allergy. Component-resolved diagnostics measuring specific IgE to profilin can help clarify whether the sensitization is profilin-driven. An allergist can interpret the full panel results in the context of the patient's geographic location and seasonal symptom pattern.

Yes, white goosefoot pollen cross-reacts with certain raw plant foods through its major allergen, Che a 1 profilin. Profilins are pan-allergens found in virtually all plant cells, meaning patients sensitized to Che a 1 may experience oral allergy syndrome — tingling, itching, or mild swelling of the lips, mouth, and throat — when eating raw fruits and vegetables that contain profilins. Commonly implicated foods include melons, watermelon, tomatoes, bananas, peaches, cherries, and celery. These reactions are typically mild and self-limited, resolving within 15–30 minutes without treatment. Cooking denatures profilin, so cooked, canned, or processed versions of the same foods are usually well-tolerated. Quinoa, a cultivated relative of white goosefoot in the Chenopodium genus, may theoretically cross-react, though documented cases are rare.

The highest-risk individuals are those living in or spending significant time in agricultural regions where Chenopodium album is an abundant weed — particularly the Midwest, Great Plains, and California's Central Valley. Farm workers, landscapers, and outdoor enthusiasts in these regions have the highest ambient pollen exposure during the July–October season. Patients with a personal or family history of atopic disease (allergic rhinitis, asthma, atopic dermatitis) are genetically predisposed to developing new pollen sensitizations. Individuals who are already sensitized to other weed pollens, grass pollens, or tree pollens — particularly those with profilin-driven poly-sensitization — are at elevated risk for cross-reactive goosefoot sensitization. Adults who relocate to goosefoot-heavy regions may develop new-onset seasonal symptoms even if they had no prior allergy history.

Yes, new-onset seasonal allergic rhinitis from weed pollens, including white goosefoot, can develop at any age. The immunological mechanism is the same regardless of age: repeated seasonal exposure to goosefoot pollen in a genetically susceptible individual eventually drives IgE sensitization and symptomatic rhinoconjunctivitis. Adult-onset pollen allergy is particularly common in people who relocate to a new geographic region with different pollen exposures — for example, someone who moves from the East Coast (where ragweed dominates) to the Midwest (where goosefoot is abundant) may develop goosefoot sensitization after several seasons of exposure. This clinical presentation — 'I never had allergies until I moved here' — should prompt evaluation with a regional weed pollen panel and is entirely consistent with adult-onset sensitization.

Allergen immunotherapy for weed pollen allergy — including white goosefoot — is well-supported by clinical evidence. Trials in weed pollen-sensitized populations demonstrate 60–80% reduction in seasonal symptom scores and medication requirements over a 3–5 year treatment course. Both subcutaneous immunotherapy (allergy shots) and sublingual immunotherapy (allergy drops) are effective, with sublingual options offering the convenience of at-home administration. The profilin cross-reactivity of Che a 1 means that immunotherapy targeting goosefoot may also reduce symptoms triggered by other profilin-containing pollens, though this cross-protection is variable. The treatment requires a long-term commitment — typically 3–5 years — but produces sustained immune tolerance that persists for years after treatment completion in most patients.

Goosefoot and pigweed are often confused because the common name 'pigweed' is applied to plants in two different genera. White goosefoot (Chenopodium album) is sometimes called pigweed, but true pigweeds belong to the genus Amaranthus. Both are in the Amaranthaceae family, both are abundant agricultural weeds, and both produce wind-dispersed pollen in late summer — so their pollen seasons overlap significantly. The allergenic proteins differ: goosefoot's major allergen is Che a 1 profilin, while amaranth allergens are less well-characterized. From a clinical perspective, the distinction matters because immunotherapy extracts are species-specific. A patient who tests positive to both may need both in their treatment formulation. An allergist can clarify which weed is driving symptoms based on skin test results and local pollen surveillance data.

Quinoa (Chenopodium quinoa) is a cultivated crop in the same genus as white goosefoot, and its seeds are consumed as a grain. While quinoa is a seed protein rather than a pollen, patients with significant Chenopodium pollen sensitization could theoretically react to quinoa protein through shared allergenic determinants. However, documented cases of quinoa allergy in goosefoot-sensitized patients are rare in the published literature, and most patients with goosefoot pollen allergy tolerate quinoa without issue. If you have a known goosefoot pollen allergy and wish to consume quinoa, you may want to discuss this with your allergist, particularly if you have a history of food allergies or oral allergy syndrome. As with any potential food allergen, introducing quinoa in a small amount while monitoring for symptoms is a reasonable approach for most patients.